Skip to main content

Table 3 Susceptibility of serial passaged HSV-2 SB5 isolates to PCV as measured by the PRA

From: Absence of rapid selection for acyclovir or penciclovir resistance following suboptimal oral prodrug therapy of HSV-infected mice

Parental SB5a

Passage No.

PCV IC50 (μg/ml)

 
  

Placebo

FCV

VCV

0.79

1

0.76 ± 0.08b

0.78 ± 0.05

0.87 ± 0.09

1.02

2

0.98 ± 0.08

0.82 ± 0.23

0.96 ± 0.27

1.06

3

1.10 ± 0.23

1.04 ± 0.22

0.87 ± 0.04

1.43

4

1.55 ± 0.15

1.02 ± 0.51

1.14 ± 0.58

1.11

5

1.32 ± 0.38

1.47 ± 0.48

1.14 ± 0.18

0.80

6

0.96 ± 0.18

0.81 ± 0.05

0.85 ± 0.16

0.90

7

0.81 ± 0.08

0.77 ± 0.05

0.82 ± 0.12

  1. aIC50 against PCV for the original parental control virus preparation (not passaged in mice). bIC50 against PCV ± standard deviation for test isolates for n = 5 samples.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us